A clinical study on a patented Phyllanthus emblica extract, commonly known as Indian gooseberry, published online in Phytomedicine, showed that Indian gooseberry caused a significant decrease in platelet aggregation. In a 10 day study, Indian gooseberry (500 mg twice daily) reduced platelet aggregation by over 36 percent, compared to 50 percent by Clopidrogel (75 mg once daily) and 51 percent by Aspirin (75 mg once daily). However, when Indian gooseberry was taken in conjunction with Clopidrogel or Aspirin, the inhibition of platelet aggregation increased only marginally to 53 percent and 56 percent, respectively. Bleeding and clotting times were not significantly affected by Indian gooseberry when used alone or in conjunction with either Clopidrogel or Aspirin.
There were also no adverse effects or bleeding events reported. An area of concern is the inhibition of platelet aggregation greater than 50 percent which is strongly correlated with bleeding events. Indian gooseberry alone produced only 27 percent and 36 percent inhibition of platelet aggregation in single dose and multiple dose studies respectively, compared to 47 percent and 50 percent for Clopidrogel and 46 percent and 51 percent for Aspirin.
This study was a randomized open label crossover study that included 10 patients with type II diabetes. Patients were evaluated both after a single dose and then with multiple doses over a 10-day period. In the single dose study, the patients were given either a dose of 500 mg of Indian gooseberry or 75 mg Clopidogrel or 75 mg Ecosprin (enteric-coated aspirin). The combination doses were 500 mg Indian gooseberry with 75 mg Clopidogrel or 500 mg Indian gooseberry with 75 mg Ecosprin. After the single dose study and wash out period, patients received the combinations for 10 days. Platelet aggregation was measured at baseline and at four hours after treatment. Bleeding and clotting times were also recorded.
"The results illustrate how Indian gooseberry may provide benefits for healthy blood circulation and heart health through reduced platelet aggregation," said Sanni Raju, Ph.D., R.Ph., chairman and CEO of Natreon. "The study was done in type 2 diabetes patients that are at a higher risk for abnormal platelet function. We're very pleased with the positive results and with growing scientific support for Indian gooseberry, we're excited about the heart health benefits it offers to dietary supplement manufacturers seeking to introduce new products or differentiate existing brands in the category," said Dr. Raju.